Colossal Biosciences Seeks Funding at $20 Billion-$30 Billion Valuation as Revenue Starts
Updated
Updated · TechCrunch · Jul 20
Colossal Biosciences Seeks Funding at $20 Billion-$30 Billion Valuation as Revenue Starts
3 articles · Updated · TechCrunch · Jul 20
Summary
Colossal Biosciences is reportedly in talks to raise fresh capital at a $20 billion to $30 billion valuation, up sharply from $10.2 billion about 16 months ago.
Axios said the five-year-old startup has begun generating revenue, supporting its pitch that the business has value beyond reviving extinct species.
That revenue case includes conservation technology offered to the U.S. government and the UAE, which recently invested $60 million in the company.
Colossal has also spun out three startups, including Form Bio, which raised $30 million, and Astromech, which was valued at $2 billion in March.
The fundraising push comes as deep-tech sectors such as longevity and alternative energy attract capital, while Colossal expands de-extinction targets and related biotech tools.
Is de-extinction a revolutionary business model worth $30 billion or a costly distraction from protecting living species?
Could Colossal's artificial womb, designed for extinct animals, offer a real solution for human infertility within the next decade?
If a woolly mammoth is resurrected by 2028, will it be a conservation triumph or an unpredictable ecological gamble?
Colossal Biosciences’ 2026 Funding Round Signals Soaring Valuation and Bold Advances in De-Extinction
Overview
Colossal Biosciences is attracting strong investor confidence as it pursues a new fundraising round in a market eager for innovative science and technology. The company’s soaring valuation is driven by its ambitious goals and major breakthroughs, such as unveiling genetically engineered dire wolves, which showcase its leadership in genetic de-extinction and conservation biotechnology. This momentum is supported by a dynamic period for deep-tech investments and broader trends in cutting-edge science, positioning Colossal Biosciences at the forefront of both industry growth and the evolving landscape of conservation technology.